Russell Ross, “Atherosclerosis—An Inflammatory Disease”, The New England Journal of Medicine, vol. 340, No. 2, Jan. 14, 1999, pp. 115-126. |
Bjarne Østerud, “A Global View on the Role of Monocytes and Platelets in Atherogenesis”, Thrombosis Research, vol. 85, No. 1, 1997 pp. 1-22. |
Artur-Aron Weber, et al., “Complex Control of Vascular Smooth Muscle Cell Growth by Thromboxane A2”, THROMB HAEMOST, vol. 80, 1998, pp. 207-208. |
Tilo Grosser, et al., “Thromboxane A2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen”, European Journal of Pharmacology, vol. 319, 1997, pp. 327-332. |
Rajbabu Pakala, et al., “Effect of Serotonin, Thromboxane A2, and Specific Receptor Antagonists of Vascular Smooth Muscle Cell Proliferation”, Circulation, vol. 96, No. 7, Oct. 1997, pp. 2280-2286. |
Agapios Sachindis, et al., “Thromboxane A2 and Vascular Smooth Muscle Cell Proliferation”, Hypertension, vol. 26, No. 5, Nov. 1995, pp. 771-780. |
David A. Jones, et al., “Activation of Thromboxane and Prostacyclin Receptors Elicits Opposing Effects on Vascular Smotth Muscle Cell Growth and Mitogen-Activated Protein Kinase Signaling Cascades”, Molecular Pharmacology, vol. 48, 1995, pp. 890-896. |
Paul M. Vanhoutte, et al., “Vascular Endothelium: Vasoactive Mediators”, Progress in Cardiovascular Disease, vol. 39, No. 3, 1996, pp. 229-238. |
Ulrich Foerstermann, et al., “Response of Human Coronary Arteries to Aggregating Platelets: Importance of Endothelium-Derived Relaxing Factor and Prostanoids”, Circulation Research, vol. 63, No. 2, 1988, pp. 306-312. |
M. W. Radomski, et al., “The Anti-aggregating Properties of Vascular Endothelium: Interactions Between Prostacyclin and Nitric Oxide”, Br. J. Pharmac, vol. 92, 1987, pp. 639-646. |
Jacques Maclouf, et al., “Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease”, THROMB HAEMOST, vol. 79, 1998, pp. 691-705. |
Julio A. Rimarachin, et al., “Regulation of Cyclooxygenase-2 Expression in Aortic Smooth Muscle Cells”, Arteriosclerosis and Thrombosis, vol. 14, vol. 7, Jul. 1994, pp. 1021-1031. |
David Bishop-Bailey, et al., “Differential Induction of Cyclooxygenase-2 in Human Arterial and Venous Smooth Muscle”, Arterioscler Thrombosis, vol. 18, 1998, pp. 1655-1661. |
Jacek Nowak, et al., “Redirection of Prostagladin Endoperoxide Metabolism at the Platelet-Vascular Interface in Man”, J. Clin. Invest., The American Society for Clinical Investigation, Inc., vol. 83, 1989, pp. 380-385. |
Jos Vermylen, et al., “Thromboxane Synthase Inhibitors and Receptor Antagonists”, Cardiovascular Drugs and Therapy, vol. 6, 1992, pp. 29-33. |
Paolo Gresele, et al., “Thromboxane Synthase Inhibitors, Thromboxane Receptor Antagonists and Dual Blockers in Thrombotic Disorders”, Trends Pharmacol Sci, vol. 12, 1991, pp. 158-163. |
Michael Emerson, et al., “Endogenous Nitric Oxide Acts as a Natural Antithrombotic Agent in Vivo by Inhibiting Platelet Aggregation in the Pulmonary Vasculature”, THROMB HAEMOST, vol. 81, 1999, pp. 961-966. |
E. Bassenge, “Endothelium-mediated Regulation of Coronary Tone”, Basic Research in Cardiology, vol. 86 (Suppl 2), 1990, pp. 69-76. |
Daniela Salvemini, et al., “Nitric Oxide-mediated Cyclooxygenase Activation”, J. Clin. Invest., The American Society for Clinical Investigation, Inc., vol. 97, No. 11, Jun. 1996, pp. 2562-2568. |